MRM-HEALTH
13.12.2022 09:01:37 CET | Business Wire | Press release
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage.
IFF joined forces with microbiome specialist MRM Health in 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary MRM Health CORAL® technology platform and some selected IFF strains will be combined to develop novel therapeutics based on live bacterial strain combinations.
“We are very pleased to see the progress that MRM Health and IFF have made within our partnership programs in metabolic health,” said Oliver Hasselwander, technical fellow, IFF. “By reaching this preclinical milestone in the diabetes program, MRM Health has further demonstrated that their technology platform is unique in identifying next generation microbiome solutions, and we look forward to developing these together with MRM Health.”
The gut microbiome has a recognized role in non-alcoholic fatty liver disease (NAFLD) and associated diseases such as Type-2 diabetes and obesity. The two companies will continue the NAFLD program to further build on promising lead consortia. IFF and MRM Health’s collaboration on NAFLD will enable both parties to build upon the preclinical results, showing that a nine-strain bacterial consortium delays NAFLD progression and liver fibrosis. Part of this work was recently published in Biomedicines.
"This second milestone achievement is an important step in demonstrating our team's expertise and the capacity of our unique CORAL® platform to deliver differentiated microbiome therapeutics across different diseases,” said Sam Possemiers, CEO and co-founder of MRM Health. “We are delighted to be working with IFF to rapidly drive the program through this preclinical phase, and we are confident that our technologies have the potential to deliver future life-changing oral therapeutics for patients."
MRM Health’s CORAL® platform utilizes a bioinformatics-guided in-human discovery engine, combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows for the development of next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost.
About MRM Health
MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in two Phase 2 studies in patients with mild-to-moderate Ulcerative Colitis and acute Pouchitis, respectively. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
** END**
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI (Formerly LambdaTest) Recognized in Independent Research on Autonomous Testing Platforms, Q4 20252.2.2026 18:24:00 CET | Press release
Research cites AI testing, data generation, and accelerated execution TestMu AI (formerly known as LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced its inclusion in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025, an independent research report evaluating vendors in the autonomous testing market. The report identifies TestMu AI as a cloud-based platform for unified test orchestration and execution. It notes the platform's capabilities in cross-browser testing, real device cloud, and AI-driven automation. Specifically, the research cites TestMu AI’s testing of AI systems across dimensions, providing metrics for accuracy, intent recognition, and hallucination detection with configurable thresholds. Additionally, the report recognizes TestMu AI’s AI-powered test data generation, citing its support for Large Language Models (LLMs), multimodal inputs, and compliance-aligned workflows. The report also noted the company's strong commun
Current Chemicals Launches as Independent Specialty Materials Manufacturer, Building on 75-Year GE Legacy with Backing from Momentum Global Ventures2.2.2026 17:04:00 CET | Press release
Today marks the debut of Current Chemicals, Inc. (CCI) as a fully independent U.S.-based specialty materials manufacturer. Backed by strategic investor Momentum Global Ventures, CCI is charting a bold new path as a trusted partner for materials innovation, custom chemistry, and U.S.-based downstream manufacturing of rare earths and critical materials. The partnership between U.S.-based CCI and Netherlands-based Momentum Global Ventures reflects a strengthening transatlantic alliance at a pivotal moment for global supply chains. This partnership underscores a shared commitment to secure, reliable, and innovation-driven materials infrastructure. Originally the chemical division of GE Lighting, the team behind CCI has served as the quiet force behind groundbreaking technologies for more than 75 years, developing processes and manufacturing advanced materials for displays, lighting, energy storage, and more. As an independent company, CCI is poised to expand its impact across industries de
Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief2.2.2026 16:00:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth. “Over the past year,
Conga Completes Acquisition of PROS B2B Business2.2.2026 15:55:00 CET | Press release
Redefines Commercial Excellence for Enterprises with a Clear Path from Price to Signature Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has completed the acquisition of the B2B business of PROS Holdings, Inc (“PROS”) from certain investment funds affiliated with Thoma Bravo, the world’s largest software-focused investment firm. This transaction unites two industry leaders to help enterprises maximize revenue, reduce risk, and improve profitability. By bringing together AI-driven pricing optimization, configuration, quoting, and contracting capabilities, the combined company creates a differentiated enterprise platform that connects the commerce chain and enables end-to-end revenue orchestration from price to signature. The expanded Conga leadership team will continue to be led by CEO Dave Osborne. “To operate as connected, intelligent businesses, enterprises need a commerce ch
Andersen Consulting styrker sit udbud inden for digital transformation gennem samarbejde med iNNOVATEQ2.2.2026 15:38:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med iNNOVATEQ, der er et Muscat-baseret digitalt transformationsfirma, der redefinerer det digitale oliefelt gennem indsigter i realtid, intelligente arbejdsgange, driftsmæssig ekspertise og produktionsoptimering på tværs af olie- og gasværdikæden. iNNOVATEQ blev grundlagt i 2018 og udsprang fra Petroleum Development of Omans (PDO) digitale transformationsprogram og trækker på en stærk operatør-DNA samt praktisk erfaring fra samarbejde med nogle af verdens største nationale og internationale olieselskaber. Virksomheden specialiserer sig i bæredygtig forretningstransformation gennem praktiske, formålstilpassede digitale løsninger leveret via deres Nibras-platform; et system til aktiv- og produktionsstyring. Med et team på mere end 100 specialister og en voksende international kundebase understøtter iNNOVATEQ sine kunder ved at kombinere digitale initiativer, effektivisering af driften og skalering af intellektuel ejendom til pålidelige
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom